4 reasons to consider NovoLog® Mix 70/30 over human premix insulin in adult patients with diabetes


Needles are sold separately and may require a prescription in some states.


Flexible dosing

Dosed within 15 minutes before or after starting a meal in patients with type 2 diabetes, unlike the required 30 minutes before meals with human premix insulin1

NovoLog® Mix 70/30 FlexPen®

Only premix insulin available in the discreet, prefilled, dial-a-dose NovoLog® Mix 70/30 FlexPen®


Needles are sold separately and may require a prescription in some states.


Cost and coverage

Similar co-pay as human premix insulin on most managed care plansa


Physiologic profile

More closely matches the body's physiologic insulin profile than human premix insulin1,2



Straight talk about premix insulin analog

Picture of Medical Doctor Joseph M. Tibaldi who shares additional info about NovoLog® Mix 70/30


Dr. Joseph M. Tibaldi shares a series of videos and additional information around NovoLog® Mix 70/30 you may encounter in your practice. Topics include physiologic profile, efficacy and safety, patient conversion, and cost and coverage.




Icon: US Territory

Look up your patients' formulary coverage

Icon: NovoLog® Mix 70/30 FlexPen® Samples

Request samples to start patients on NovoLog® Mix 70/30

Icon: Dollar Symbol

Share the Novo Nordisk Instant Savings Card with eligible patients


a Managed care plans only. Does not include Medicaid. Multiple products within the same therapeutic class may be considered preferred and on the same tier.

Selected Important Safety Information

  • NovoLog® Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® Mix 70/30 or one of its excipients.
  • Never Share a NovoLog® Mix 70/30 FlexPen® Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
  • NovoLog® Mix 70/30 should not be mixed with any other insulin product, administered intravenously, or used in insulin infusion pumps. NovoLog® Mix 70/30 has a faster onset of action than human insulin premix 70/30 and should be dosed within 15 minutes before meal initiation for patients with type 1 diabetes. For patients with type 2 diabetes, dosing should occur within 15 minutes before or after meal initiation. 

NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Indications and Usage

  • NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus.

Important Limitations of Use

  • In premix insulins, such as NovoLog® Mix 70/30, the proportions of rapid-acting and long-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. 

Important Safety Information

Contraindications

  • NovoLog® Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® Mix 70/30 or one of its excipients. 

Warnings and Precautions

  • Never Share a NovoLog® Mix 70/30 FlexPen® Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
  • Administration: NovoLog® Mix 70/30 should not be mixed with any other insulin product, administered intravenously, or used in insulin infusion pumps. NovoLog® Mix 70/30 has a faster onset of action than human insulin premix 70/30 and should be dosed within 15 minutes before meal initiation for patients with type 1 diabetes. For patients with type 2 diabetes, dosing should occur within 15 minutes before or after meal initiation.
  • Hypoglycemia: Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin dose should be made cautiously and only under medical supervision.
  • Hypokalemia: Insulin, particularly when given in settings of poor glycemic control, can cause hypokalemia. Use caution in patients predisposed to hypokalemia.
  • Renal and Hepatic Impairment: Like all insulins, NovoLog® Mix 70/30 requirements may be reduced in patients with renal impairment or hepatic impairment.
  • Hypersensitivity and Allergic Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog® Mix 70/30.
  • Fluid retention and heart failure can occur with concomitant use of PPAR-gamma agonists: Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog® Mix 70/30.

Adverse Reactions

  • Adverse reactions observed with insulin therapy include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. 

Use in Specific Populations

  • The safety and effectiveness of NovoLog® Mix 70/30 have not been established in pediatric patients. Clinical studies of NovoLog® Mix 70/30 did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients. 

The significance, with respect to the long-term clinical sequelae of diabetes, of the differences in postprandial hyperglycemia between treatment groups has not been established.

Please click here for Prescribing Information.

 

References

  1. NovoLog® Mix 70/30 [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2015.
  2. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation: pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care. 1997;20(10):1612-1614.